These findings demonstrate combination treatment with galunisertib plus nivolumab has an acceptable safety profile in patients with refractory or recurrent NSCLC who received prior platinum-based treatment and were treatment-naive for anti-PD-(L)1 or TGF-β receptor 1 kinase inhibitors. Here, CD274 is linked to non-small cell lung carcinoma.